1.Pharmacotherapy for erectile dysfunction.
National Journal of Andrology 2005;11(8):626-630
In the recent few years, especially since the introduction of phosphodiesterase-5 inhibitor, sildenafil, most researchers have focused their researches on biochemistry and physiology of erectile function. New progress has been made made in basic and clinic researches on pharmacotherapy for ED. In this article, the putative molecular or cellular mechanism of actions of the available centrally and peripherally acting drugs are reviewed, providing details about the current and most explosive area of drug research and development in erectile dysfunction.
Animals
;
Apomorphine
;
pharmacology
;
therapeutic use
;
Erectile Dysfunction
;
drug therapy
;
Humans
;
Male
;
Phosphodiesterase Inhibitors
;
pharmacology
;
therapeutic use
;
Piperazines
;
pharmacology
;
therapeutic use
;
Purines
;
pharmacology
;
therapeutic use
;
Rats
;
Sildenafil Citrate
;
Sulfones
;
pharmacology
;
therapeutic use
;
Yohimbine
;
pharmacology
;
therapeutic use
2.Advances in the treatment of erectile dysfunction by viagra.
National Journal of Andrology 2005;11(4):314-319
Viagra has become the first line drug for the treatment of erectile dysfunction since it was first introduced in 1998. Its efficacy and safety have been sidely acclaimed as being definite. This article presents a brief review about the advances in the studies of Viagra, including its therapeutic effect and safety, its protection of penile health, and its promotion of self-esteem and sexual relationship.
Erectile Dysfunction
;
drug therapy
;
Humans
;
Male
;
Penile Erection
;
drug effects
;
Personal Satisfaction
;
Phosphodiesterase Inhibitors
;
pharmacology
;
therapeutic use
;
Piperazines
;
pharmacology
;
therapeutic use
;
Purines
;
pharmacology
;
therapeutic use
;
Sildenafil Citrate
;
Sulfones
;
pharmacology
;
therapeutic use
3.CAL-101,a novel agent of targeted therapy in hematological malignancies.
Chan-Juan LI ; Qing ZHANG ; Yi-Zhuo ZHANG
Journal of Experimental Hematology 2014;22(2):530-533
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. It has been determined that the P110δ isoforms of PI3K expressed primarily in cells of hematopoietic lineage, such as B and T cells. This review focuses on the target, mechanism of action, the use and prospect of CAL-101 in tumors of blood and lymph systems.
Animals
;
Class Ia Phosphatidylinositol 3-Kinase
;
antagonists & inhibitors
;
Hematologic Neoplasms
;
drug therapy
;
Humans
;
Purines
;
pharmacology
;
therapeutic use
;
Quinazolinones
;
pharmacology
;
therapeutic use
;
Signal Transduction
;
drug effects
4.Selective serotonin reuptake inhibitors in the treatment of premature ejaculation.
Wei-fu WANG ; Le CHANG ; Suks MINHAS ; David J RALPH
Chinese Medical Journal 2007;120(11):1000-1006
OBJECTIVETo review and assess the update studies regarding selective serotonin reuptake inhibitors (SSRIs) in the treatment of premature ejaculation (PE) and then provide practical recommendations and possible mechanisms concerning state of the art knowledge for the use of SSRIs in alleviating PE.
DATA SOURCESUsing the Medline, 48 articles published from January 1st, 1996 to August 1st, 2006 concerning the use of SSRIs and their possible mechanisms in alleviating PE were found and reviewed.
STUDY SELECTIONPE, rapid ejaculation, early ejaculation and SSRIs were employed as the keywords, and relevant articles about the use of SSRIs and their possible mechanisms in the treatment of PE were selected.
RESULTSMany kinds of SSRIs, such as fluoxetine, sertraline, paroxetine and citalopram, have widely been employed to treat PE. However, their effects are moderate and there is no a universal agreement about the kind, dose, protocol and duration. Dapoxetine, as the first prescription treatment of PE, may change this bottle-neck situation. SSRIs are suggested to be used in young men with lifelong PE, and acquired PE when etiological factors are removed but PE still exists. Phosphodiesterase 5 inhibitors (PDE(5)-Is) are suggested to be employed alone or combined with SSRIs when SSRIs fail to treat PE or sexual dysfunction associated with SSRIs occurs. The protocol of taking drugs on demand based on taking them daily for a suitable period is proposed to be chosen firstly. The possible mechanisms include increasing serotonergic neurotransmission and activating 5-hydroxytryptamine 2C (5-HT(2C)) receptors, then switching the ejaculatory threshold to a higher level, decreasing the penile sensitivity and their own effect of antidepression.
CONCLUSIONThe efficacies of the current SSRIs are moderate in the treatment of PE and they have not been approved by the FDA, therefore new SSRI like dapoxetine needs to be further evaluated.
Clinical Trials as Topic ; Ejaculation ; drug effects ; Humans ; Male ; Piperazines ; therapeutic use ; Purines ; therapeutic use ; Serotonin Uptake Inhibitors ; adverse effects ; pharmacology ; therapeutic use ; Sexual Dysfunction, Physiological ; drug therapy ; Sildenafil Citrate ; Sulfones ; therapeutic use
5.Research on cyclin-dependent kinase inhibitors: state of the art and perspective.
Ming-xin ZUO ; Xiao-guang CHEN
Chinese Journal of Oncology 2007;29(5):321-324
Animals
;
Antineoplastic Agents
;
pharmacology
;
therapeutic use
;
Cell Cycle
;
drug effects
;
physiology
;
Cyclin-Dependent Kinases
;
antagonists & inhibitors
;
metabolism
;
Cyclins
;
metabolism
;
Flavonoids
;
pharmacology
;
therapeutic use
;
Humans
;
Neoplasms
;
drug therapy
;
metabolism
;
pathology
;
Piperidines
;
pharmacology
;
therapeutic use
;
Purines
;
pharmacology
;
therapeutic use
;
Staurosporine
;
analogs & derivatives
;
pharmacology
;
therapeutic use
6.Researches on the establishment of chronic nephropathy models and the effect of TCM on these models.
Zhi-qing GAO ; Yue-yi DENG ; Lin WANG ; Yi-ping CHEN
Chinese Journal of Integrated Traditional and Western Medicine 2005;25(2):186-189
Following contents were reviewed in this article: More and more experimental studies related with chronic uratic nephropathy were carried out in recent years. In most of these studies, the animal models were established mainly from viewpoints of gene recombination, urinary uric acid inhibition and blood uric acid production promoting. TCM showed good effects in lowering blood uric acid, regulating levels of cytokines and postponing interstitial fibrosis. However, further studies on Chinese herbs and their extracts is necessary.
Animals
;
Disease Models, Animal
;
Drugs, Chinese Herbal
;
pharmacology
;
therapeutic use
;
Hyperuricemia
;
blood
;
Kidney Diseases
;
etiology
;
Mice
;
Phytotherapy
;
Purines
;
metabolism
;
Rats
;
Uric Acid
;
blood
7.Therapeutic efficacy of Bushengzhuyang Fang (Yangjing Capsule) on phytoestrogen-induced erectile dysfunction: an experimental study.
Yu-Chun ZHOU ; Tian-Fu LI ; Zhi-Xing SUN ; Qian FAN ; Tao LIU ; Bao-Fang JIN
National Journal of Andrology 2014;20(12):1103-1108
OBJECTIVETo investigate the effect of Bushengzhuyang Fang (Yangjing Capsule, YJC) on penile erectile function and its action mechanisms in rats.
METHODSFifty-six male SD rats were randomly divided into seven groups of equal number: blank control, daidzein, daidzein + testosterone, daidzein + sildenafil, daidzein + low-dose YJC, daidzein + medium-dose YJC, and daidzein + high-dose YJC. The rats in the blank control group were treated intragastrically with normal saline and those in the other groups with daidzein at the dose of 100 mg per kg per day for 30 days. Then the last five groups received additionally testosterone (4 mg per kg per day), sildenafil (2.5 mg per kg per day), low-dose YJC, (0.315 mg per kg per day), medium-dose YJC (0.63 mg per kg per day), and high-dose YJC (1. 26 mg per kg per day), respectively. At 0, 30 and 60 days of treatment, we observed the apomorphine-induced spontaneous erectile response and pathological changes in the corpus cavernosum of the rats, recorded the number of penile erection and erectile incubation period, and determined the serum levels of testosterone (T) and luteinizing hormone (LH).
RESULTSAt 30 days of treatment, the number of apomorphine-induced erections was decreased, the erectile incubation period prolonged, and the serum levels of T and LH reduced remarkably in all groups of rats (P < 0.05). Compared with the findings at 30 days, the number of penile erections was significantly decreased at 60 days in the daidzein group (1.39 ± 0.42 vs 2.67 ± 0.33, P < 0.05) and daidzein + low-dose YJC group (1.33 ± 0.49 vs 2.83 ± 0.61, P < 0.05); the erectile incubation period was markedly ex- tended ([16.33 ± 3.11] vs [8.50 ± 0.93] min and [15.50 ± 3.21] vs [8.63 ± 1.54] min, P < 0.05); and the serum levels of T ([5.34 ± 0.89] vs [1.24 ± 0.30] ng/ml and [5.28 ± 1.12] vs [2.07 ± 0.76] ng/ml, P < 0.05) and LH ([3.62 ± 0.37] vs [2.09 ± 0.12] ng/ml and [3.79 ± 0.28] vs [2.17 ± 0.33] ng/ml, P < 0.05) were significantly reduced in the daidzein and daidzein + low-dose YJC groups, respectively. Pathological examination revealed slightly decreased cavernous sinuses and blood vessels in the corpus cavernosum of the rats in the daidzein + testosterone, daidzein + sildenafil, daidzein + medium-dose YJC, and daidzein + high-dose YJC groups as compared with those in the blank control group.
CONCLUSIONHigh-dose Yangjing Capsule is efficacious for the recovery of erectile function in rats, especially for phytoestrogen-induced erectile dysfunction.
Animals ; Apomorphine ; pharmacology ; Drugs, Chinese Herbal ; therapeutic use ; Erectile Dysfunction ; chemically induced ; drug therapy ; Humans ; Isoflavones ; pharmacology ; Luteinizing Hormone ; Male ; Penile Erection ; drug effects ; physiology ; Penis ; drug effects ; pathology ; Phytoestrogens ; Phytotherapy ; Piperazines ; therapeutic use ; Purines ; therapeutic use ; Rats ; Rats, Sprague-Dawley ; Sildenafil Citrate ; Sulfonamides ; therapeutic use ; Testosterone ; therapeutic use ; Vasodilator Agents ; therapeutic use
8.Role of PKG-L-type calcium channels in the antinociceptive effect of intrathecal sildenafil.
Woong Mo KIM ; Myung Ha YOON ; Jin Hua CUI
Journal of Veterinary Science 2010;11(2):103-106
Sildenafil increases the cyclic guanosine monophosphate (cGMP) by inhibition of a phosphodiesterase 5, thereby leading to an antinociceptive effect. The increased cGMP may exert the effect on an L-type calcium channel through the activation of protein kinase G (PKG). The purpose of this study was to examine the possible involvement of a PKG-L-type calcium channel on the effect of sildenafil at the spinal level. Catheters were inserted into the intrathecal space of male SD rats. Pain was induced by applying 50 microliter of a 5% formalin solution to the hindpaw. The sildenafil-induced effect was examined after an intrathecal pretreatment of a PKG inhibitor (KT 5823), or a L-type calcium channel activator (FPL 64176). Intrathecal sildenafil produced an antinociceptive effect during phase 1 (0~10 min interval) and phase 2 (10~60 min interval) in the formalin test. Intrathecal KT 5823 and FPL 64176 attenuated the antinociceptive effect of sildenafil during both phases. Sildenafil is effective against both acute pain and the facilitated pain state at the spinal level. In addition, the inhibition of an L-type calcium channel by activation of the PKG may contribute to the antinocieptive mechanism of sildenafil in the spinal cord.
Animals
;
Calcium Channel Agonists/pharmacology
;
Calcium Channels, L-Type/*physiology
;
Carbazoles/pharmacology
;
Cyclic GMP-Dependent Protein Kinases/antagonists & inhibitors/*physiology
;
Dose-Response Relationship, Drug
;
Male
;
Pain/drug therapy/*physiopathology
;
Pain Measurement
;
Piperazines/*pharmacology/therapeutic use
;
Protein Kinase Inhibitors/pharmacology
;
Purines/pharmacology/therapeutic use
;
Pyrroles/pharmacology
;
Rats
;
Rats, Sprague-Dawley
;
Sulfones/*pharmacology/therapeutic use
9.Effect of Sildenafil on Neuropathic Pain and Hemodynamics in Rats.
Lan Ji HUANG ; Myung Ha YOON ; Jeong Il CHOI ; Woong Mo KIM ; Hyung Gon LEE ; Yeo Ok KIM
Yonsei Medical Journal 2010;51(1):82-87
PURPOSE: The inhibition of phosphodiesterase 5 produces an antinociception through the increase of cyclic guanosine monophosphate (cGMP), and increasing cGMP levels enhance the release of gamma-aminobutyric acid (GABA). Furthermore, this phosphodiesterase 5 plays a pivotal role in the regulation of the vasodilatation associated to cGMP. In this work, we examined the contribution of GABA receptors to the effect of sildenafil, a phosphodiesterase 5 inhibitor, in a neuropathic pain rat, and assessed the hemodynamic effect of sildenafil in normal rats. MATERIALS AND METHODS: Neuropathic pain was induced by ligation of L5/6 spinal nerves in Sprague-Dawley male rats. After observing the effect of intravenous sildenafil on neuropathic pain, GABAA receptor antagonist (bicuculline) and GABAB receptor antagonist (saclofen) were administered prior to delivery of sildenafil to determine the role of GABA receptors in the activity of sildenafil. For hemodynamic measurements, catheters were inserted into the tail artery. Mean arterial pressure (MAP) and heart rate (HR) were measured over 60 min following administration of sildenafil. RESULTS: Intravenous sildenafil dose-dependently increased the withdrawal threshold to the von Frey filament application in the ligated paw. Intravenous bicuculline and saclofen reversed the antinociception of sildenafil. Intravenous sildenafil increased the magnitude of MAP reduction at the maximal dosage, but it did not affect HR response. CONCLUSION: These results suggest that sildenafil is active in causing neuropathic pain. Both GABAA and GABAB receptors are involved in the antinociceptive effect of sildenafil. Additionally, intravenous sildenafil reduces MAP without affecting HR.
Animals
;
Baclofen/analogs & derivatives/pharmacology
;
Bicuculline/pharmacology
;
Blood Pressure/drug effects
;
Dose-Response Relationship, Drug
;
Heart Rate/drug effects
;
Hemodynamics/drug effects
;
Male
;
Neuralgia/*drug therapy
;
Pain Threshold/drug effects
;
Phosphodiesterase Inhibitors/*therapeutic use
;
Piperazines/*therapeutic use
;
Purines/therapeutic use
;
Rats
;
Rats, Sprague-Dawley
;
Receptors, GABA-A/antagonists & inhibitors/physiology
;
Receptors, GABA-B/antagonists & inhibitors/physiology
;
Sulfones/*therapeutic use
10.Roles of Adenosine and Serotonin Receptors on the Antinociception of Sildenafil in the Spinal Cord of Rats.
Hyung Gon LEE ; Woong Mo KIM ; Cheon Hee PARK ; Myung Ha YOON
Yonsei Medical Journal 2010;51(6):960-964
PURPOSE: The phosphodiesterase 5 inhibitor sildenafil has antinociceptive effects, mediated by an increase in cGMP. This study examined the role of spinal adenosine and serotonin receptors played in the antinociceptive effects of intrathecal sildenafil. MATERIALS AND METHODS: Intrathecal catheters were inserted into the subarachnoid space of Sprague-Dawley male rats as a drug delivery device. Pain was induced by injecting formalin into the plantar surface of rats and observing nociceptive behavior (flinching response) for 60 mininutes. Then, the effects of intrathecal adenosine and serotonin receptor antagonists on the antinociceptive activity of intrathecal sildenafil were examined. RESULTS: Intrathecal sildenafil suppressed the flinching response in a dose-dependent manner during phases 1 and 2 in the formalin test. Both CGS 15943 and dihydroergocristine decreased the antinociceptive effects of sildenafil during phases 1 and 2 in the formalin test. CONCLUSION: Intrathecal sildenafil effectively attenuated the pain evoked by formalin injection. Both adenosine and serotonin receptors may be involved in the antinociceptive action of sildenafil at the spinal level.
Adenosine/metabolism
;
Analgesics/*therapeutic use
;
Animals
;
Cyclic GMP/metabolism
;
Dihydroergocristine/pharmacology
;
Injections, Spinal
;
Male
;
Pain/*drug therapy
;
Piperazines/*pharmacology
;
Purines/pharmacology
;
Rats
;
Rats, Sprague-Dawley
;
Receptors, Purinergic P1/*metabolism
;
Receptors, Serotonin/*metabolism
;
Spinal Cord/*metabolism
;
Sulfones/*pharmacology
;
Vasodilator Agents/therapeutic use